Fate Therapeutics Inc. buy marge
Start price
27.06.19
/
50%
€17.84
Target price
04.11.21
€82.00
Performance (%)
183.83%
End price
05.11.21
€50.64
Summary
This prediction ended on 05.11.21 with a price of €50.64. The BUY prediction by marge for Fate Therapeutics Inc. saw massive gains of 183.83%. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Fate Therapeutics Inc. | 6.975% | 6.975% | 178.685% | -40.367% |
| iShares Core DAX® | -2,68 % | 2,02 % | 3,06 % | 56,11 % |
| iShares Nasdaq 100 | 0,73 % | 2,75 % | 34,40 % | 92,06 % |
| iShares Nikkei 225® | -0,73 % | 5,70 % | 63,75 % | 79,14 % |
| iShares S&P 500 | 1,17 % | 4,06 % | 25,14 % | 70,02 % |
Comments by marge for this prediction
In the thread Fate Therapeutics Inc. diskutieren
marge stimmt der Buy-Einschätzung der Analysten zu
Piper Jaffray is reissuing its Buy rating on Fate Therapeutics (FATE) today, but lifting its price target seven bucks a share to $30. Piper's analyst states 'the company remains a top pick for the second half of 2019 given its "first-in-class iPSC cancer cell pipeline'.
Kursziel geändert auf 32,0
Kursziel geändert auf 82,0
In the thread Trading Fate Therapeutics Inc.
Die von marge gewählte maximale Laufzeit wurde überschritten